FCM
CGEM icon

Farallon Capital Management’s Cullinan Oncology CGEM Stock Holding History

Farallon Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-125,000
Closed -$5.21M – 302
2021
Q1 		$5.21M Buy
+125,000
New +$5.07M 0.03% 184

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Farallon Capital Management's CGEM Position: Q2 2021 in Review

Farallon Capital Management sold out of Cullinan Oncology (CGEM) in Q2 2021, closing a stake of 125,000 shares — an estimated $5.21M sold.

Farallon Capital Management first reported a position in CGEM in Q1 2021 and held it in 1 quarter. The position peaked at $5.21M in Q1 2021. 71 funds tracked by Wall St. Rank hold CGEM as of Q2 2021.

  • Farallon Capital Management reported no remaining Cullinan Oncology position as of Q2 2021 after selling out during the quarter.
  • Farallon Capital Management sold 125,000 Cullinan Oncology shares in Q2 2021, an estimated $5.21M.
  • Farallon Capital Management first reported a position in Cullinan Oncology in Q1 2021 and held it in 1 quarter.
  • Farallon Capital Management's Cullinan Oncology position peaked at $5.21M in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2021.

Based on Farallon Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.